|
|
|
 
Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice
| Table 1: Characteristics of patients with atrial fibrillation from 2 practice settings, by treatment |
|
| |
Treatment |
| |
|
| Characteristic |
ASA
n = 31 |
Warfarin
n = 87 |
Blended*
n = 65 |
None
n = 38 |
|
|
Mean age (and SD), yr |
73.1 |
(8.6) |
70.8 |
(8.8) |
70.7 |
(9.5) |
73.9 |
(10.3) |
|
% male |
16 |
(52) |
57 |
(66) |
41 |
(63) |
28 |
(74) |
|
Concomitant condition, no. (and %) of patients |
|
|
|
|
|
|
|
|
| Angina |
8 |
(26) |
18 |
(21) |
14 |
(22) |
6 |
(16) |
| Myocardial infarction |
8 |
(26) |
26 |
(30) |
9 |
(14) |
6 |
(16) |
| Congestive heart failure |
7 |
(23) |
30 |
(34) |
18 |
(28) |
13 |
(34) |
| Hypertension |
12 |
(39) |
37 |
(43) |
32 |
(49) |
20 |
(53) |
| Diabetes mellitus† |
0 |
|
21 |
(24) |
23 |
(35) |
7 |
(18) |
| Hypercholesterolemia |
5 |
(16) |
15 |
(17) |
12 |
(18) |
5 |
(13) |
| Prior stroke† |
0 |
|
18 |
(21) |
7 |
(11) |
1 |
(3) |
|
Duration of atrial fibrillation |
|
|
|
|
|
|
|
|
 1 yr |
6 |
(19) |
18 |
(21) |
18 |
(28) |
11 |
(29) |
| > 1 yr |
17 |
(55) |
58 |
(67) |
42 |
(65) |
20 |
(53) |
| Unknown |
8 |
(26) |
11 |
(13) |
5 |
(8) |
7 |
(18) |
|
Note: SD = standard deviation.
*Patients who switched treatment groups.
†p < 0.001 for comparison of all 4 groups. |
|
[Return to text]
|